Despite recent rapid progress in understanding the expression patterns and regulatory mechanisms of drug processing genes, namely drug metabolizing enzymes and transporters in adults, little is known about these in the pediatric period. The long-term goal is to understand mechanisms of ontogenic regulation of drug processing genes, so that efficacious and safe drug treatments can be achieved in children. Several factors are known to be essential for normal development, including hepatocyte nuclear factor 11 (HNF11), farnesoid X receptor (FXR), growth hormone (GH) signaling, and epigenetic influences. HNF11, a master regulator of early liver development, regulates hepatic expression of a large battery of drug processing genes. Initiation of bile-acid signaling pathways, mediated largely via the FXR, is a hallmark of perinatal liver development. GH is essential for postnatal hepatic gene expression and maturation. The accessibility of transcription factors to the target genes is largely determined by the methylation/acetylation status of histones and DNA sequences. Preliminary studies illustrate that in developing mouse livers, drug processing genes and transcription factors are expressed in distinct dynamic patterns and correlate with epigenetic signatures. The objective of this proposal is to elucidate the regulatory mechanisms of ontogenic expression of drug processing genes in mice. The rationale of this proposal is that its successful completion will generate basic knowledge that will serve as the foundation for further understanding pediatric pharmacology in humans. The central hypothesis is: developmental regulation of drug processing genes is a sequential event regulated by hormones, which activate transcription factors to modify epigenetic signatures and regulate gene expression. This hypothesis will be tested in 2 aims.
Aim 1 will determine the ontogenic expression patterns of drug processing genes and the correlation with transcription factors and epigenetic signatures. The relative mRNA expression of major phase I/II enzymes and drug transporters in male mouse livers versus intestine and kidney will be examined, and correlated with expression of transcription factors and chromosome modifications (genome-wide DNA methylation and histone modifications).
Aim 2 will elucidate roles of transcription factors and GH in determining ontogenic hepatic expression of drug processing genes in HNF11-null, FXR-null, and GH deficiency (lit/lit) mice using the same working strategy. This study is novel, because it will use a genome-wide approach to elucidate how alterations of hormones and transcription factors modulate epigenetic signatures and hepatic ontogenic expression of drug processing genes. This study is significant, because little is known about the regulation of hepatic drug processing genes in pediatric stages. Results from this study will: 1) provide basic knowledge on the ontogenic expression patterns of drug processing genes and nuclear receptors in liver, kidney, and intestine;and 2) help to understand how perinatal alterations in hormones and nuclear receptors, via modulating epigenetic signatures, affect stage-specific and long-term expression of drug processing genes.

Public Health Relevance

The proposed studies are of importance and an under-investigated area of regulatory mechanisms of the developmental expression patterns of genes important in the absorption, distribution, metabolism, and excretion of therapeutic drugs. Thus, the findings are expected to be applicable to the improvement of efficacy and safety of pediatric pharmacology.

National Institute of Health (NIH)
National Institute of Environmental Health Sciences (NIEHS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-CB-L (50))
Program Officer
Tyson, Frederick L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Kansas
Internal Medicine/Medicine
Schools of Medicine
Kansas City
United States
Zip Code
Bao, Yifan; Ma, Xiaochao; Rasmussen, Theodore P et al. (2018) Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury. Curr Pharmacol Rep 4:171-181
Lu, Hong; Lei, Xiaohong; Zhang, Qinghao (2018) Liver-specific knockout of histone methyltransferase G9a impairs liver maturation and dysregulates inflammatory, cytoprotective, and drug-processing genes. Xenobiotica :1-13
Dempsey, Joseph; Zhang, Angela; Cui, Julia Yue (2018) Coordinate regulation of long non-coding RNAs and protein-coding genes in germ-free mice. BMC Genomics 19:834
Dzierlenga, Anika L; Cherrington, Nathan J (2018) Misregulation of membrane trafficking processes in human nonalcoholic steatohepatitis. J Biochem Mol Toxicol 32:e22035
Li, Cindy Yanfei; Dempsey, Joseph L; Wang, Dongfang et al. (2018) PBDEs Altered Gut Microbiome and Bile Acid Homeostasis in Male C57BL/6 Mice. Drug Metab Dispos 46:1226-1240
Dempsey, Joseph L; Cui, Julia Yue (2017) Long Non-Coding RNAs: A Novel Paradigm for Toxicology. Toxicol Sci 155:3-21
Piekos, Stephanie; Pope, Chad; Ferrara, Austin et al. (2017) Impact of Drug Treatment at Neonatal Ages on Variability of Drug Metabolism and Drug-drug Interactions in Adult Life. Curr Pharmacol Rep 3:1-9
Guo, Ying; Cui, Julia Yue; Lu, Hong et al. (2017) Effect of nine diets on mRNAs of phase-II conjugation enzymes in livers of mice. Xenobiotica 47:645-654
Fu, Zidong Donna; Cui, Julia Yue (2017) Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites. Curr Pharmacol Rep 3:101-113
Li, Cindy Yanfei; Lee, Soowan; Cade, Sara et al. (2017) Novel Interactions between Gut Microbiome and Host Drug-Processing Genes Modify the Hepatic Metabolism of the Environmental Chemicals Polybrominated Diphenyl Ethers. Drug Metab Dispos 45:1197-1214

Showing the most recent 10 out of 80 publications